Serevent Side Effects Lawsuit News

FDA Meets on Safety of Glaxo Asthma Drug

11/28/2007 - Government advisers on Wednesday will consider whether a GlaxoSmithKline asthma drug poses greater risks to children than to adults.

The Food and Drug Administration has asked a panel of outside experts to review Glaxo's Serevent as part of a three-day meeting on the safety of medicines taken by children.

Serevent is an inhalable drug that contains the same key ingredient as Advair, London-based Glaxo's top-selling product. Last year, FDA added a "black box" warning, the most serious a drug can carry, to both drugs, cautioning that they can increase the risk of asthma-related death.

Adults are instructed to use inhalable steroid therapy alongside Serevent and Advair to offset their risks. But FDA said ahead of the meeting that steroidal therapy may not have the same protective effect in children.

FDA will ask its experts whether additional studies are needed to judge the benefits and risks of Serevent and other asthma drugs in children.

Sales of Serevent totaled $602 million last year. The drug's U.S. patent is due to expire in 2008.

If you or a loved one have been injured by or have lost a loved one due to Serevent side effects you may be entitled to compensation. Click here or call toll free, 1-800-856-6405, to speak to our Serevent lawyer regarding the Serevent lawsuit. Our Serevent attorney and our on staff registered nurse are standing by to answer your questions regarding Serevent litigation or Serevent side effects.